Assess whether RWE can replace or only supplement an RCT (c7c2c5)

Situation

Labeling negotiator owns RWE can replace or inside a 505(b)(2) program relying on literature plus a bridging study with 505(b)(2) literature-to-product bridge table as the only packet. A site-change that invalidates stability claims is what changed the clock for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose RWE can replace / Only supplement an RCT using 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims.

Hypotheses to test

• 505(b)(2) literature-to-product bridge table reads as RWE can replace once a site-change that invalidates stability claims is lined up to the same Pharma & Life Sciences population.
• 505(b)(2) literature-to-product bridge table is closer to Only supplement an RCT after a site-change that invalidates stability claims; RWE can replace would over-claim this CMC and Development Pathways extract.
• A dual reading is still live in 505(b)(2) literature-to-product bridge table for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.
• 505(b)(2) literature-to-product bridge table is missing the fact labeling negotiator needs after a site-change that invalidates stability claims; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a site-change that invalidates stability claims and write the one fact that would move RWE can replace or for labeling negotiator.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.